NCT01468558View on ClinicalTrials.gov

Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconazole

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Healthy
Interventions
DRUG

MAP0004

MAP0004 1.0mg via inhalation on Day 1 and Day 6 of Visit 2

DRUG

IV DHE

IV DHE (Intravenous Dihydroergotamine Mesylate) administered at Visit 3

DRUG

Ketoconazole

Ketoconazole 400 mg administered once a day on days 3-6 of Visit 2

Trial Locations (1)

Unknown

Simbec Research Limited, Merthyr Tydfil

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
collaborator

MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan

INDUSTRY

lead

Allergan

INDUSTRY

NCT01468558 - Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconazole | Biotech Hunter | Biotech Hunter